2. Academic Validation
  3. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease

Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease

  • Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11392-11397. doi: 10.1073/pnas.1705748114.
Elizaveta S Leshchiner 1 2,  Jason S Rush 3,  Michael A Durney 3,  Zhifang Cao 4 5 6,  Vlado Dančík 2,  Benjamin Chittick 2,  Huixian Wu 2,  Adam Petrone 3,  Joshua A Bittker 3,  Andrew Phillips 3,  Jose R Perez 3,  Alykhan F Shamji 2,  Virendar K Kaushik 3,  Mark J Daly 7 8,  Daniel B Graham 4 5 6,  Stuart L Schreiber 9 2,  Ramnik J Xavier 10 5 6
Affiliations

Affiliations

  • 1 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138.
  • 2 Center for the Science of Therapeutics, Broad Institute, Cambridge, MA 02142.
  • 3 Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142.
  • 4 Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • 5 Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • 6 Infectious Disease and Microbiome Program, Broad Institute, Cambridge, MA 02142.
  • 7 Medical and Population Genetics Program, Broad Institute, Cambridge, MA 02142.
  • 8 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114.
  • 9 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138; [email protected] [email protected].
  • 10 Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; [email protected] [email protected].
PMID: 29073062 DOI: 10.1073/pnas.1705748114
Abstract

Advances in human genetics have dramatically expanded our understanding of complex heritable diseases. Genome-wide association studies have identified an allelic series of CARD9 variants associated with increased risk of or protection from inflammatory bowel disease (IBD). The predisposing variant of CARD9 is associated with increased NF-κB-mediated cytokine production. Conversely, the protective variant lacks a functional C-terminal domain and is unable to recruit the E3 ubiquitin ligase TRIM62. Here, we used biochemical insights into CARD9 variant proteins to create a blueprint for IBD therapeutics and recapitulated the mechanism of the CARD9 protective variant using small molecules. We developed a multiplexed bead-based technology to screen compounds for disruption of the CARD9-TRIM62 interaction. We identified compounds that directly and selectively bind CARD9, disrupt TRIM62 recruitment, inhibit TRIM62-mediated ubiquitinylation of CARD9, and demonstrate cellular activity and selectivity in CARD9-dependent pathways. Taken together, small molecules targeting CARD9 illustrate a path toward improved IBD therapeutics.

Keywords

CARD9; inflammatory bowel disease; small molecules; therapeutics.

Figures
Products